Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial
ANDHI was done to assess the efficacy of bevacizumab in treating severe eosinophilic asthma. It was a randomized, double-blind, parallel-group, placebo-controlled study. The primary efficacy measure was annualized asthma exacerbation rate. Our results extend the efficacy profile of bevacizumab for patients with severe eosinophilic asthma, showing early clinical benefits in patient-reported outcomes, HRQOL, lung function, and nasal polyposis symptoms.
